TY - JOUR
T1 - Association of Hearing Loss With Neuropsychiatric Symptoms in Older Adults With Cognitive Impairment
AU - Kim, Alexander S.
AU - Garcia Morales, Emmanuel E.
AU - Amjad, Halima
AU - Cotter, Valerie T.
AU - Lin, Frank R.
AU - Lyketsos, Constantine G.
AU - Nowrangi, Milap A.
AU - Mamo, Sara K.
AU - Reed, Nicholas S.
AU - Yasar, Sevil
AU - Oh, Esther S.
AU - Nieman, Carrie L.
N1 - Funding Information:
CGL has received grant support (research or continuing medical education) from the National Institute of Mental Health, the National Institute on Aging, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, the National Football League (NFL), Elan, Functional Neuromodulation, and the Bright Focus Foundation; he is a consultant or adviser for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, Orion, Otsuka, Servier, Astellas, Roche, Karuna, SVB Leerink, Maplight, and Axsome and he has received honorariums or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. FRL is a consultant to Boeringher-Ingelheim and Autifony Inc. FRL reports being a consultant to Frequency Therapeutics, speaker honoraria from Caption Call, and being the director of a research center funded in part by a philanthropic gift from Cochlear Ltd to the Johns Hopkins Bloomberg School of Public Health. FRL and CLN are board members of the nonprofit Access HEARS. CLN is a member of the board of trustees for the Hearing Loss Association of America. This study was supported in-part by funding from the National Institutes of Health (NIA K23AG059900, CLN; NIA R01AG057725, and Roberts Family Fund, ESO; NIA P30AG066507, CGL; NIA K23DC016855 SKM). For the remaining authors none were declared.
Funding Information:
CGL has received grant support (research or continuing medical education) from the National Institute of Mental Health, the National Institute on Aging, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, GlaxoSmithKline, Eisai, Pfizer, AstraZeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, the National Football League (NFL), Elan, Functional Neuromodulation, and the Bright Focus Foundation; he is a consultant or adviser for AstraZeneca, GlaxoSmithKline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, Elan, the NFL Players Association, NFL Benefits Office, Avanir, Zinfandel, BMS, Abvie, Janssen, Orion, Otsuka, Servier, Astellas, Roche, Karuna, SVB Leerink, Maplight, and Axsome and he has received honorariums or travel support from Pfizer, Forest, GlaxoSmithKline, and Health Monitor. FRL is a consultant to Boeringher-Ingelheim and Autifony Inc. FRL reports being a consultant to Frequency Therapeutics, speaker honoraria from Caption Call, and being the director of a research center funded in part by a philanthropic gift from Cochlear Ltd to the Johns Hopkins Bloomberg School of Public Health. FRL and CLN are board members of the nonprofit Access HEARS. CLN is a member of the board of trustees for the Hearing Loss Association of America. This study was supported in-part by funding from the National Institutes of Health ( NIA K23AG059900 , CLN; NIA R01AG057725 , and Roberts Family Fund, ESO; NIA P30AG066507 , CGL; NIA K23DC016855 SKM ). For the remaining authors none were declared.
Publisher Copyright:
© 2020 American Association for Geriatric Psychiatry
PY - 2021/6
Y1 - 2021/6
N2 - Neuropsychiatric symptoms (NPS) in persons with dementia (PWD) are common and can lead to poor outcomes, such as institutionalization and mortality, and may be exacerbated by sensory loss. Hearing loss is also highly prevalent among older adults, including PWD. Objective: This study investigated the association between hearing loss and NPS among community- dwelling patients from a tertiary memory care center. Design, Setting, and Participants: Participants of this cross-sectional study were patients followed at the Johns Hopkins Memory and Alzheimer's Treatment Center who underwent audiometric testing during routine clinical practice between October 2014 and January 2017. Outcome Measurements: Included measures were scores on the Neuropsychiatric Inventory–Questionnaire and the Cornell Scale for Depression in Dementia. Results: Participants (n = 101) were on average 76 years old, mostly female and white, and had a mean Mini-Mental State Examination score of 23. We observed a positive association between audiometric hearing loss and the number of NPS (b = 0.7 per 10 dB; 95% confidence interval [CI]: 0.2, 1.1; t = 2.86; p = 0.01; df = 85), NPS severity (b = 1.3 per 10 dB; 95% CI: 0.4, 2.5; t = 2.13; p = 0.04; df = 80), and depressive symptom severity (b = 1.5 per 10 dB; 95% CI: 0.4, 2.5; t = 2.83; p = 0.01; df = 89) after adjustment for demographic and clinical characteristics. Additionally, the use of hearing aids was inversely associated with the number of NPS (b = −2.09; 95% CI −3.44, −0.75; t = −3.10; p = 0.003; df = 85), NPS severity (b = −3.82; 95% CI −7.19, −0.45; t = −2.26; p = 0.03; df = 80), and depressive symptom severity (b = −2.94; 95% CI: −5.93, 0.06; t = 1.70; p = 0.05; df = 89). Conclusion: Among patients at a memory clinic, increasing severity of hearing loss was associated with a greater number of NPS, more severe NPS, and more severe depressive symptoms, while hearing aid use was associated with fewer NPS, lower severity, and less severe depressive symptoms. Identifying and addressing hearing loss may be a promising, low-risk, non-pharmacological intervention in preventing and treating NPS.
AB - Neuropsychiatric symptoms (NPS) in persons with dementia (PWD) are common and can lead to poor outcomes, such as institutionalization and mortality, and may be exacerbated by sensory loss. Hearing loss is also highly prevalent among older adults, including PWD. Objective: This study investigated the association between hearing loss and NPS among community- dwelling patients from a tertiary memory care center. Design, Setting, and Participants: Participants of this cross-sectional study were patients followed at the Johns Hopkins Memory and Alzheimer's Treatment Center who underwent audiometric testing during routine clinical practice between October 2014 and January 2017. Outcome Measurements: Included measures were scores on the Neuropsychiatric Inventory–Questionnaire and the Cornell Scale for Depression in Dementia. Results: Participants (n = 101) were on average 76 years old, mostly female and white, and had a mean Mini-Mental State Examination score of 23. We observed a positive association between audiometric hearing loss and the number of NPS (b = 0.7 per 10 dB; 95% confidence interval [CI]: 0.2, 1.1; t = 2.86; p = 0.01; df = 85), NPS severity (b = 1.3 per 10 dB; 95% CI: 0.4, 2.5; t = 2.13; p = 0.04; df = 80), and depressive symptom severity (b = 1.5 per 10 dB; 95% CI: 0.4, 2.5; t = 2.83; p = 0.01; df = 89) after adjustment for demographic and clinical characteristics. Additionally, the use of hearing aids was inversely associated with the number of NPS (b = −2.09; 95% CI −3.44, −0.75; t = −3.10; p = 0.003; df = 85), NPS severity (b = −3.82; 95% CI −7.19, −0.45; t = −2.26; p = 0.03; df = 80), and depressive symptom severity (b = −2.94; 95% CI: −5.93, 0.06; t = 1.70; p = 0.05; df = 89). Conclusion: Among patients at a memory clinic, increasing severity of hearing loss was associated with a greater number of NPS, more severe NPS, and more severe depressive symptoms, while hearing aid use was associated with fewer NPS, lower severity, and less severe depressive symptoms. Identifying and addressing hearing loss may be a promising, low-risk, non-pharmacological intervention in preventing and treating NPS.
KW - Hearing loss
KW - cognitive impairment
KW - dementia
KW - hearing care
KW - neuropsychiatric symptoms
UR - http://www.scopus.com/inward/record.url?scp=85095820988&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85095820988&partnerID=8YFLogxK
U2 - 10.1016/j.jagp.2020.10.002
DO - 10.1016/j.jagp.2020.10.002
M3 - Article
C2 - 33168388
AN - SCOPUS:85095820988
SN - 1064-7481
VL - 29
SP - 544
EP - 553
JO - American Journal of Geriatric Psychiatry
JF - American Journal of Geriatric Psychiatry
IS - 6
ER -